Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced that its Board of Directors will convene on October 19, 2026. The primary agenda for this meeting is to consider, approve, and take on record the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. In line with the company's insider trading code, the trading window for designated persons will be closed from October 1, 2026, until 48 hours after the financial results are publicly disclosed. The company will also make this information available on its website.

Tatva Chintan Pharma Chem Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The trading window will remain shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. This measure is standard practice to prevent insider trading during periods of sensitive financial information disclosure.

Tatva Chintan Pharma Chem Ltd has announced the record date for its final dividend for FY 2025-26 as September 11, 2026. The company's Register of Members and Share Transfer Books will be closed from September 12, 2026, to September 25, 2026, inclusive, for the 30th Annual General Meeting (AGM). The AGM is scheduled for September 25, 2026, at 4:00 p.m. IST, to be held via Video Conference. The dividend, if approved, will be paid on or after October 1, 2026. Additionally, September 18, 2026, has been fixed as the cut-off date for shareholders to exercise their e-voting rights.

Tatva Chintan Pharma Chem Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by SEBI Listing Regulations. The report, which forms part of the Annual Report, is available on the company's website. The BRSR details the company's corporate identity, business activities in specialty chemicals (98.94% of turnover), products like Structure Directing Agents (40.74%), Phase Transfer Catalysts (23.12%), and Pharmaceutical/Agrochemical Intermediates (33.05%). It also outlines operations across 17 states nationally and 30 countries internationally, with exports contributing 75% of turnover. Employee data, including 363 permanent employees and 734 permanent workers, is provided, along with details on differently-abled personnel and gender representation on the Board (16.67% female) and Key Management Personnel (0% female). The reporting is on a standalone basis.

Tatva Chintan Pharma Chem Ltd has filed its Annual Report and Notice of the 30th Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM is scheduled for Friday, September 25, 2026, at 04:00 p.m. (IST) and will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company is distributing the Annual Report electronically to members with registered email addresses and via a web-link and QR code for others. The report highlights the company's 30-year journey, operational excellence across its Ankleshwar and Dahej facilities, R&D capabilities, and its impact on industrial efficiency, cleaner living, and future technologies. It also details financial statements, corporate governance, and sustainability initiatives.

Tatva Chintan Pharma Chem Ltd has announced its 30th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 4:00 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, declaration of dividend, and the re-appointment of a director retiring by rotation. Additionally, the company will seek approval for the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director for a period of three years from February 1, 2027, including fixation of remuneration.

Tatva Chintan Pharma Chem Ltd has announced the resignation of Mr. Ajay Rawat, Assistant Vice President – Research and Development, who is designated as Senior Management Personnel. His resignation was accepted by the management on August 19, 2026, and will be effective from the close of business hours on November 13, 2026. Mr. Rawat cited pursuing career opportunities outside the company as the reason for his departure. The company has provided the necessary disclosures as per SEBI regulations.

Tatva Chintan Pharma Chem Ltd announced that its Board of Directors recommended a final dividend of ₹2.00 per equity share (20%) for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming 30th Annual General Meeting. The company also provided details regarding Tax Deduction at Source (TDS) for both resident and non-resident shareholders, outlining applicable rates and conditions for tax exemption or lower withholding tax, including the requirement for specific forms and declarations.

Tatva Chintan Pharma Chem Ltd announced the Groundbreaking Ceremony (Bhoomi Pujan) for its new greenfield manufacturing unit at Dahej - III, Gujarat. This event, held on July 20, 2026, follows an earlier intimation on July 17, 2026. The new facility is a strategic move to bolster the company's infrastructure and cater to increasing market demands, aligning with its growth strategy. The company will make this information available on its website.

Tatva Chintan Pharma Chem Limited's Board of Directors approved a significant capacity expansion for specialty chemicals at their new greenfield unit in Dahej, Gujarat. This expansion aims to strengthen infrastructure and meet growing market demands. Additionally, the board approved an increase in the company's borrowing limits from ₹300 crore to ₹1,000 crore, subject to shareholder approval. The meeting also saw the approval of unaudited financial results for the quarter ended June 30, 2026, and the re-appointment of three key directors: Mr. Chintan Nitinkumar Shah (Managing Director), Mr. Ajaykumar Mansukhlal Patel (Whole-time Director), and Mr. Shekhar Rasiklal Somani (Whole-time Director), each for a three-year term starting February 1, 2027.